FEM1B抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: PC3 cells, Primary antibody: P04874(FEM1B Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P04874(FEM1B Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of FEM1B Antibody**

The FEM1B antibody targets the FEM1B protein, a member of the FEM1 (Fanconi anemia-associated E3 ubiquitin ligase) family, which plays a role in ubiquitination pathways and cellular processes such as apoptosis, development, and stress responses. FEM1B acts as a substrate-recognition subunit in E3 ubiquitin ligase complexes, facilitating protein degradation via the ubiquitin-proteasome system. It is implicated in regulating signaling pathways, including the Hedgehog pathway, and interacts with proteins like CUL2 and APP (amyloid precursor protein), linking it to neurodegenerative diseases such as Alzheimer’s.

Research using FEM1B antibodies has highlighted its involvement in cancer progression, particularly in prostate cancer and neuroblastoma, where dysregulation may influence tumor growth or suppression. FEM1B antibodies are essential tools for detecting protein expression, localization, and interaction partners via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. These studies help elucidate FEM1B’s dual roles—either as a tumor suppressor or oncogene, depending on cellular context—and its potential as a therapeutic target. Commercial FEM1B antibodies are typically raised against specific epitopes (e.g., C-terminal regions) and validated for cross-reactivity and specificity across human and model organisms. Ongoing research aims to clarify its mechanistic contributions to disease and normal physiology.